C/D for EMA? Good luck! [Two-Stage / GS Designs]

posted by Helmut Homepage – Vienna, Austria, 2012-09-01 17:09 (4612 d 22:07 ago) – Posting: # 9140
Views: 21,455

Hi GSD!

❝ […] I realized that 10^6 is a must when you go for Potvin’s 2-stage.


Yes – 1/√N hits.*

❝ ❝ Which one of Potvin’s methods are you aiming at?


❝ Methods C/D.


Are you aware that the acceptability of C/D for EMA is limited (pun intended)? If you want to deal with ABEL, I reckon only Method B might be acceptable – though some member states even mistrust the validity of the power evaluation in the intermediate analysis at all. Right now C/D is only acceptable (without major discussions) in the US and Canada. Since HPFB does not allow scaling this leaves the FDA with an easier model (without the 50% cap – but the discontinuity at 30%).

❝ But if any of your sample CVs exceeds 30%, the acceptance limits are widened. They are no longer fixed at 0.8 and 1.25. When you enter your simulation with a starting CV of say 35%, most of your random samples will have an acceptance limit in the neighborhood of [0.7723, 1.2948]. In this case, when you still center it on ln(0.8), the simulated “type I error” will be huge.


Sounds like chicken-and-egg to me. :-D The ratio and CV in the sims are independent – but the scaled acceptance range depends on the actual CV in every simulated study…



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,699 registered users;
30 visitors (0 registered, 30 guests [including 4 identified bots]).
Forum time: 15:17 CEST (Europe/Vienna)

Do not put your faith in what statistics say until you have carefully
considered what they do not say.    William W. Watt

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5